• / Free eNewsletters & Magazine
  • / My Account
Home>Stocks>Alkermes

Alkermes

  1. All
  2. Morningstar Articles
  3. 3rd Party
  1. Alkermes Initiates Phase 3 Gastrointestinal Tolerability Study of ALKS 8700 for Treatment of Multiple Sclerosis

    Alkermes Initiates Phase 3 Gastrointestinal Tolerability Study of ALKS 8700 for Treatment of Multiple Sclerosis

  2. Our Take on the Fund Manager of the Year Winners

    Morningstar analysts explain what makes the award winners stand out.

  3. Morningstar Rating for Stocks Performance Update

    With the first half of 2005 in the rearview mirror, it's time for another review of how the stock star rating is doing. I'm happy to report that after lagging a bit in the first quarter, we've now pulled ahead of most of our benchmarks. The First Half of 2005 As a reminder, we measure our ...

  4. How the Stock Star Rating Is Performing

    With 2004 in the rearview mirror, I thought I'd share another Morningstar Rating for stocks performance review with you. Our results continue to be positive, which makes this a pleasant review to write. As before, we're measuring ourselves by creating a hypothetical portfolio that buys 5-star ...

©2017 Morningstar Advisor. All right reserved.